Use of more expensive insulin despite guidelines in Brazil.

Autor:	Mendonça TS; Programa de Pós-Graduação Em Ciências da Saúde, Federal University of São João Del-Rei (UFSJ), Campus Centro-Oeste Dona Lindu (CCO), Brazil., Silva ES; Programa de Pós-Graduação Em Ciências da Saúde, Federal University of São João Del-Rei (UFSJ), Campus Centro-Oeste Dona Lindu (CCO), Brazil., Pereira ML; Programa de Pós-Graduação Em Ciências da Saúde, Federal University of São João Del-Rei (UFSJ), Campus Centro-Oeste Dona Lindu (CCO), Brazil., Obreli-Neto PR; Departamento de Farmácia, Centro Universitário Das Faculdades Integradas de Ourinhos (UniFIO), Brazil., Belo VS; Programa de Pós-Graduação Em Ciências da Saúde, Federal University of São João Del-Rei (UFSJ), Campus Centro-Oeste Dona Lindu (CCO), Brazil., Ferreira GC; Curso de Medicina, Federal University of São João Del-Rei (UFSJ), Campus Centro-Oeste Dona Lindu (CCO), Brazil., Chaves PRD; Curso de Medicina, Federal University of São João Del-Rei (UFSJ), Campus Centro-Oeste Dona Lindu (CCO), Brazil., Baldoni AO; Programa de Pós-Graduação Em Ciências da Saúde, Federal University of São João Del-Rei (UFSJ), Campus Centro-Oeste Dona Lindu (CCO), Brazil. Electronic address: andrebaldoni@ufsj.edu.br.
Jazyk:	angličtina
Zdroj:	Diabetes & metabolic syndrome [Diabetes Metab Syndr] 2020 Mar - Apr; Vol. 14 (2), pp. 155-157. Date of Electronic Publication: 2020 Feb 11.
DOI:	10.1016/j.dsx.2020.02.005
Abstrakt:	Aim: To verify if the guidelines are being followed for the treatment of patients with type 1 diabetes mellitus (T1DM) who receive insulin by lawsuits. Methods: A descriptive study was conducted with secondary data of these patients in a Brazilian city. Results: 53.9% acquired insulin by lawsuits without previously registered use of another insulin in the Public Health System (SUS). Conclusion: The guidelines are not being followed for most patients analyzed, which may result in unnecessary expenses for the SUS. Therefore, this data can support the awareness of prescribers in relation to the savings generated for municipalities through the follow-up of the guidelines. Competing Interests: Declaration of competing interest None. (Copyright © 2020 Diabetes India. Published by Elsevier Ltd. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Full Text from ScienceDirect